Thermo Fisher Scientific (NYSE:TMO) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Thermo Fisher Scientific (NYSE:TMO) had its price objective upped by Stifel Nicolaus from $650.00 to $775.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 11.67% from the company’s previous close.

A number of other brokerages have also recently weighed in on TMO. Scotiabank initiated coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an “outperform” rating on the stock. UBS Group upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their target price for the company from $540.00 to $730.00 in a research note on Tuesday, September 8th. CLSA initiated coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price target for the company. Piper Sandler began coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an “overweight” rating on the stock. Finally, Guggenheim assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, October 15th. They set a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $670.29.

Thermo Fisher Scientific Stock Up 1.0%

Shares of Thermo Fisher Scientific stock opened at $693.98 on Thursday. The business’s fifty day moving average price is $642.42 and its two-hundred day moving average price is $552.67. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market capitalization of $256.60 billion, a P/E ratio of 37.33, a PEG ratio of 2.87 and a beta of 0.87. Thermo Fisher Scientific has a 1-year low of $435.27 and a 1-year high of $705.79.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The company had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the prior year, the business posted $5.79 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. As a group, research analysts forecast that Thermo Fisher Scientific will post 25.13 EPS for the current year.

Insider Activity

In other news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. This trade represents a 7.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is owned by company insiders.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMO. BlackRock Inc. bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $15,501,867,000. Corient Private Wealth LP bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $382,547,000. Bank of New York Mellon Corp acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $1,974,561,000. Bank of America Corp DE acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Thermo Fisher Scientific by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after buying an additional 22,827 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Quarterly results exceeded expectations: Q3 revenue rose 9.1% year over year to $12.14 billion, while adjusted EPS increased 15% to $6.68, beating consensus estimates of $11.95 billion and $6.40, respectively. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Growth broadened across key end markets: Organic revenue growth reached 6%, supported by pharmaceutical demand, clinical research, bioproduction and electron microscopy. Management also highlighted continued customer activity, AI integration and signs of recovery in previously weaker markets. TMO Q3 deep dive
• Positive Sentiment: Profitability and outlook improved: Operating margin reached 24.5%, aided by portfolio actions and productivity initiatives. Thermo Fisher raised its full-year 2026 revenue and earnings outlook, including a 4% organic revenue-growth target. Three key takeaways
• Positive Sentiment: Analyst confidence increased: Robert W. Baird raised its price target from $723 to $756 and upgraded or reaffirmed an “outperform” rating, implying additional upside from the current trading level.
• Neutral Sentiment: Investors delivered a measured response: Despite the earnings beat and higher guidance, the stock’s reaction has been relatively restrained, suggesting that strong results may have been partly anticipated and that valuation remains an important consideration. Q3 earnings disconnect
• Negative Sentiment: Short-term caution remains: Early trading included selling pressure following the report, and put-option purchases rose about 52% above average volume, indicating that some investors are hedging against volatility or disappointment after the earnings release.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.